Aequus Pharmaceuticals Inc. is expected to receive a Notice of Compliance from Health Canada for the launch of Zimed® PF (bimatoprost 0.03% ophthalmic solution), the first Preservative Free bimatoprost eye drop for patients with open-angle glaucoma or ocular hypertension. Health Canada approval is expected before year end 2022. Aequus Pharma is anticipating a Health Canada approval by December 31, 2022 for Zimed® PF in a multi-dose format.
Zimed® PF will provide eye care professionals and patients a new option for the treatment of open-angled glaucoma and ocular hypertension.